Results 301 to 310 of about 102,703 (336)

Hyperthermic Intraperitoneal Chemotherapy

Advances in Anesthesia, 2005
Cancer treatment frequently requires a multimodality approach, involving surgical resection(s), radiotherapy, and chemotherapy. Advanced surgical approaches allow for the combination of two of these, offering patients intraoperative radiotherapy with surgical resection or intraoperative chemotherapy targeted and limited to a particular body region. The
Alicia M. Kowalski, Thomas B. Dougherty
openaire   +1 more source

Intraperitoneal Chemotherapy and Immunotherapy

1988
1. The predictive model is validated empirically; a kinetic advantage for i.p. administration of certain antineoplastic drugs exist. 2. The concentrations achieved in the peritoneum are orders of magnitude greater than those found in the plasma, so rate-limiting systemic toxicities may be avoided. 3.
B E, Wolf, P H, Sugarbaker
openaire   +2 more sources

Concepts in intraperitoneal chemotherapy

Seminars in Oncology Nursing, 1987
NTRAPERITONEAL (IP) chemotherapy is the administration of chemotherapeutic agents via a catheter into the peritoneal cavity. The chemotherapy is placed in a large volume of fluid, usually 2 L, and infused into the abdominal cavity where it remains for a specified amount of time; then it is usually drained back out the catheter.
openaire   +2 more sources

Laparoscopical insertion of intraperitoneal catheters for intraperitoneal chemotherapy

Acta Obstetricia et Gynecologica Scandinavica, 2003
Background and methods.  Eight patients (seven clinically negative stage Ill ovarian cancer and one peritoneal mesothelioma) respectively underwent second‐look laparoscopy for staging, adhesiolysis and insertion of an intraperitoneal catheter and fixation of a portal.
Anaf, Vincent, Gangji, Diamon, Simon, Philippe, Saylam, Keziban   +3 more
openaire   +2 more sources

Intraperitoneal chemotherapy for ovarian cancer

Current Oncology Reports, 2003
Intraperitoneal chemotherapy provides a means by which high concentrations of drugs and long durations of tissue exposure can be attained at the peritoneal surface. It has been studied widely in ovarian cancer, a disease in which intra-abdominal progression remains the major source of morbidity and mortality.
Gregory, Friberg, Gini, Fleming
openaire   +2 more sources

Intraperitoneal chemotherapy for ovarian cancer

Current Opinion in Oncology, 2006
Intraperitoneal chemotherapy for ovarian cancer is based on sound pharmacological principles and is technically feasible. There is mounting evidence, bolstered by a recent randomized trial, that in certain patients, this route of delivery may be superior to traditional intravenous chemotherapy.
Chad A, Hamilton, Jonathan S, Berek
openaire   +2 more sources

Intraperitoneal chemotherapy for colorectal cancer

Journal of Surgical Oncology, 2001
AbstractThe peritoneal surface remains an important failure site for patients with colorectal cancer. Peritoneal metastases of colorectal cancer are at present considered equal to distant metastatic disease. Consequently, peritoneal carcinomatosis is treated with systemic chemotherapy and surgery only to palliate complications such as obstruction ...
Eelco, de Bree, A J, Witkamp, Frans A N, Zoetmulder   +2 more
openaire   +2 more sources

Hyperthermic Intraperitoneal Chemotherapy

2017
Peritoneal metastasis in abdominal malignancies is associated with a dismal prognosis. In the past, it was considered inoperable and the patient was considered a candidate for palliative chemotherapy alone. The outcome of systemic chemotherapy is poor with the average survival being 6–8 months.
Nikhil Gupta, Shivendra Singh
openaire   +1 more source

Carrier solutions for intraperitoneal chemotherapy

Surgical Oncology Clinics of North America, 2003
Two pharmacokinetic problems appear to limit the effectiveness of intraperitoneal therapy: poor tumor penetration and nonuniform intraperitoneal distribution by the drug-containing solution. A better understanding of the pharmacodynamics of carrier solutions for intraperitoneal chemotherapy may impact on both these problems.
Faheez, Mohamed, Paul H, Sugarbaker
openaire   +2 more sources

Neutropenia following Perioperative Intraperitoneal Chemotherapy

Tumori Journal, 1999
Introduction The purpose of this retrospective report was to evaluate clinical features associated with profound neutropenia in patients with peritoneal carcinomatosis who were treated with heated intraoperative intraperitoneal chemotherapy (HIIC) followed by early postoperative intraperitoneal chemotherapy (EPIC).
K J, Schnake, P H, Sugarbaker, D, Yoo
openaire   +2 more sources